(IN BRIEF) Brenntag has signed an exclusive European distribution agreement with ArcticZymes AS for its line of salt-active nucleases—SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP—used in gene therapy, vaccine manufacturing, and bioprocessing. Signed during the CPHI fair … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Industrial, Management, Pharma & Biotech
Tagged ArcticZymes, biopharma, biopharmaceutical innovation, bioprocessing, biotechnology, Brenntag, Brenntag and ArcticZymes Join Forces to Support Growth in Biopharmaceutical and Gene Therapy Markets, CPHI Frankfurt, downstream processing, enzyme distribution, enzymes, European partnership, gene therapy, GMP, Joakim Rehné, life sciences, M-SAN HQ, nucleases, Paul Blackburn, SAN HQ, vaccine manufacturing
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) The EIB has extended a €150 million loan to Alfasigma to fund its R&D efforts from 2025 to 2027, targeting new drugs in gastroenterology, hepatology, vascular medicine, rheumatology, and rare diseases. The financing, endorsed by EIB Vice-President Gelsomina … Read the full press release
Posted in Banks, Business, Economy, Financial, Government, Healthcare, Industrial, Investment, Italy, Luxembourg, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Alfasigma, biopharmaceutical innovation, EIB, European competitiveness, European Investment Bank, gastroenterology, Gelsomina Vigliotti, hepatology, job creation, partnership, patient-centred therapies, R&D financing, rare diseases, rheumatology, specialty care, Tatiana Simonelli, Vascular Medicine
Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and development together at purpose-built facility on Cambridge Biomedical Campus 21-6-2013 — /europawire.eu/ — AstraZeneca today announced that its new UK-based global research and development centre and corporate headquarters will be located … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?